<?xml version="1.0" encoding="UTF-8"?>
<p>Another parameter that might offer some prediction is to assess if the MICs found are above or below the serum levels obtained for each antifungal agent. For most of the antifungal agents, attainable serum levels have been determined (Table 
 <xref rid="tbl3" ref-type="table">3</xref>).
 <xref rid="bib49" ref-type="bibr">
  <sup>49</sup>
 </xref> For itraconazole, the therapeutic goal for invasive fungal infections is to reach a blood trough level &gt;1–2 µg/ml itraconazole.
 <xref rid="bib49" ref-type="bibr">
  <sup>49</sup>
 </xref> This is a concentration above the MIC50 for 
 <italic>M. mycetomatis</italic>, 
 <italic>M. pseudomycetomatis</italic>, 
 <italic>M. tropicana</italic>, 
 <italic>F. senegalensis</italic>, F
 <italic>. tomkinsii</italic>, 
 <italic>T. grisea</italic>, 
 <italic>N. mackinnonii</italic>, 
 <italic>E. grisea</italic>, 
 <italic>E. paragrisea</italic> and 
 <italic>E. jeanselmei</italic>, but not for 
 <italic>M. fahalii</italic> and 
 <italic>M. romeroi</italic> (Table 
 <xref rid="tbl3" ref-type="table">3</xref>)
 <italic>. M. fahalii</italic> and 
 <italic>M. romeroi</italic> both have an MIC50 for posaconazole that is attainable in serum (Table 
 <xref rid="tbl3" ref-type="table">3</xref>). For terbinafine, a serum level of 2.8–3 µg/ml was modelled at the dosages used to treat mycetoma. This concentration is lower than the MICs determined for 
 <italic>M. mycetomatis</italic> (Table 
 <xref rid="tbl1" ref-type="table">1</xref>)
 <italic>.</italic>
</p>
